This innovative book provides a unique perspective on the biomedical and societal implications of personalized medicine and how it will help mitigate the healthcare crisis and rein in ever-growing expenditure. It introduces the reader to underlying concepts at the heart of personalized medicine - pharmacogenomics, targeted therapies and individualized diagnosis and treatment - and shows how, with the advent of genomic technologies, clinicians will have the capability to predict and diagnose disease more efficiently. Advocating a patient-centred approach at the heart of care, this introduction to personalized medicine, the science behind it, its economic effects, its effects upon patients and its overall implications for society will be invaluable to clinicians, to healthcare providers and to patients.
Table of Contents
Acknowledgements. Preface. Introduction: Biomedical Innovation and Policy in the 21st Century. The Rise of Genomics and Personalized Medicine. Patient Narratives: Personalized Medicine in the Field. Alliances: Knowledge Infrastructures and Precision Medicine. Great Strides in Precision Medicine: Personalized Oncology and Molecular Diagnostics. Personalized Medicine’s Impact on Disease. The Genome in the Clinic: Diagnosis, Treatment and Education. A New Set of Clinical Tools for Physicians. The Regulatory Landscape. Translational Personalized Medicine: Molecular Profiling, Druggable Targets and Clinical Genomic Medicine. The Economics of Personalized Medicine. Moral and Ethical Issues: Claims, Consequences, and Caveats. Conclusion.
Priya Hays has an A.B. from Dartmouth College and a Master’s in Genetics and Ph.D. in Literature from the University of California. She also conducted research at Dartmouth Medical School for her postdoctoral fellowship. She has taught science writing at Santa Clara University and San Francisco State University. Currently, she is a technical writer at Cepheid Corporation, Sunnyvale, California, USA. Her research interests in biomedicine involve social and cultural aspects of medicine and health, public understanding of genetic testing, stem cell research, and areas in biomedical ethics. She also has an interest in science and technology policy, focusing on biomedical and nanotechnology policy.